

## Alexa Fluor<sup>®</sup> 700 anti-mouse CD3 Antibody

<b>Catalog# / Size</b>	100215 / 25 µg 100216 / 100 µg
<b>Clone</b>	17A2
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	T cell antigen receptor complex, T3
<b>Isotype</b>	Rat IgG2b, κ
<b>Description</b>	CD3, also known as T3, is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 is composed of CD3ε, δ, γ and ζ chains. It forms a TCR complex by associating with TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	γδTCR-positive T-T hybridoma D1
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography and conjugated with Alexa Fluor <sup>®</sup> 700 under optimal conditions.
<b>Concentration</b>	0.5 mg/ml
<b>Storage &amp; Handling</b>	The CD3 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	<p>Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a>. The suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is highly recommended that the reagent be titrated for optimal performance for each application.</p> <p>* Alexa Fluor<sup>®</sup> 700 has a maximum emission of 719 nm when it is excited at 633 nm / 635 nm. Prior to using Alexa Fluor<sup>®</sup> 700 conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.</p> <p>Alexa Fluor<sup>®</sup> and Pacific Blue™ are trademarks of Life Technologies Corporation.</p> <p><a href="#">View full statement regarding label licenses</a></p>
<b>Excitation Laser</b>	Red Laser (633 nm)
<b>Application Notes</b>	Additional reported application (for relevant formats) include: spatial biology (IBEX) <sup>1,2</sup> .
<b>Application References</b> (PubMed link indicates BioLegend citation)	<ol style="list-style-type: none"><li>1. Radtke AJ, <i>et al.</i> 2020. <i>Proc Natl Acad Sci U S A.</i> 117:33455-65. (SB) <a href="#">PubMed</a></li><li>2. Radtke AJ, <i>et al.</i> 2022. <i>Nat Protoc.</i> 17:378-401. (SB) <a href="#">PubMed</a></li></ol>
<b>Product Citations</b>	<ol style="list-style-type: none"><li>1. Hirai T, <i>et al.</i> 2020. <i>Immunity.</i> 54(1):84-98.e5. <a href="#">PubMed</a></li><li>2. Cignarella F <i>et al.</i> 2018. <i>Cell metabolism.</i> 27(6):1222-1235. <a href="#">PubMed</a></li><li>3. Kwong Chung CK, <i>et al.</i> 2017. <i>Immunology.</i> 150:221. <a href="#">PubMed</a></li><li>4. Abdul-Careem MF, <i>et al.</i> 2012. <i>PLoS One.</i> 7:e32821. <a href="#">PubMed</a></li><li>5. Wojno E, <i>et al.</i> 2011. <i>J Immunol.</i> 187:266. <a href="#">PubMed</a></li></ol>

6. Roco JA *et al.* 2019. *Immunity*. 51(2):337-350 . [PubMed](#)
7. Hirata Y *et al.* 2018. *Cell stem cell*. 22(3):445-453 . [PubMed](#)
8. Groenen AG, *et al.* 2022. *J Lipid Res*. 63:100167. [PubMed](#)
9. Fisher E, *et al.* 2021. *Front Immunol*. 11:602254. [PubMed](#)
10. Turner JS *et al.* 2018. *Cell reports*. 25(6):1395-1403 . [PubMed](#)
11. Delás MJ, *et al.* 2019. *Cell Rep*. 27:719. [PubMed](#)
12. Jiang W, *et al.* 2022. *Front Immunol*. 13:878832. [PubMed](#)
13. Toomer G, *et al.* 2022. *Viruses*. 14:. [PubMed](#)
14. Chow MT *et al.* 2019. *Immunity*. 50(6):1498-1512 . [PubMed](#)
15. Zhang C, *et al.* 2020. *Cell Metabolism*. 31(1):148-161.e5.. [PubMed](#)
16. Zhang H, *et al.* 2020. *Cancer Cell*. 37(1):37-54.e9.. [PubMed](#)
17. Ma YV, *et al.* 2021. *MAbs*. 13:2003281. [PubMed](#)
18. Teng ZX, *et al.* 2022. *J Inflamm Res*. 15:3187. [PubMed](#)
19. Yu M, *et al.* 2021. *J Clin Invest*. 131:. [PubMed](#)
20. Yang Y, *et al.* 2021. *Nat Commun*. 12:525. [PubMed](#)
21. Gary EN, *et al.* 2021. *iScience*. 24(7):102699. [PubMed](#)
22. Willingham SB, *et al.* 2018. *Cancer Immunol Res*. 6:1136. [PubMed](#)
23. Jiang H, *et al.* 2021. *Oncoimmunology*. 10:1943180. [PubMed](#)
24. Leonard JD *et al.* 2017. *Immunity*. 47(1):107-117 . [PubMed](#)
25. Miska J *et al.* 2019. *Cell reports*. 27(1):226-237 . [PubMed](#)
26. Watanabe K, *et al.* 2018. *JCI Insight*. 3. [PubMed](#)
27. Zhang L, *et al.* 2021. *Methods Mol Biol*. 2388:175. [PubMed](#)
28. Levescot A, *et al.* 2021. *J Clin Invest*. 131:. [PubMed](#)
29. Everard A, *et al.* 2014. *Nat Commun*. 5:5648. [PubMed](#)
30. Tyagi AM, *et al.* 2021. *eLife*. 10:00. [PubMed](#)
31. Leylek R, *et al.* 2019. *Cell Rep*. 29:3736. [PubMed](#)
32. Progozky F, *et al.* 2021. *Nature*. 599:125. [PubMed](#)
33. Gary E, *et al.* 2020. *Vaccine*. 3821:38. [PubMed](#)
34. Li Q, *et al.* 2019. *Front Pharmacol*. 10:786. [PubMed](#)
35. Zeng Q, *et al.* 2022. *Front Immunol*. 13:740805. [PubMed](#)
36. Reese B, *et al.* 2020. *J Immunol*. 205:3218. [PubMed](#)
37. La Rose AM, *et al.* 2021. *Mol Metab*. 53:101265. [PubMed](#)
38. Sharma M, *et al.* 2020. *Circ Res*. 127:335. [PubMed](#)
39. Li A, *et al.* 2020. *J Virol*. 94:00:00. [PubMed](#)
40. Kaur A, *et al.* 2019. *Cancer Discov*. 9:64. [PubMed](#)
41. Kiniry BE, *et al.* 2018. *J Immunol*. 200:1876. [PubMed](#)
42. Liu S, *et al.* 2020. *Cell Host & Microbe*. 26(6):779-794.e8.. [PubMed](#)
43. Kuhn JA, *et al.* 2021. *Elife*. 10:. [PubMed](#)
44. Green WD, *et al.* 2022. *J Leukoc Biol*. 111:147. [PubMed](#)
45. Wu S, *et al.* 2022. *BMC Immunol*. 23:17. [PubMed](#)
46. Mantilla-Rojas C, *et al.* 2022. *Cancers (Basel)*. 14:. [PubMed](#)
47. Bendtsen SK, *et al.* 2022. *Oncoimmunology*. 11:2026020. [PubMed](#)
48. Koelwyn GJ, *et al.* 2020. *Nat Med*. 1452:26. [PubMed](#)
49. Bruder J, *et al.* 2017. *Mol Ther Methods Clin Dev*. 10.1016/j.omtm.2017.08.003. [PubMed](#)
50. Echevarría-Vargas IM, *et al.* 2018. *EMBO Mol Med*. 10:e8446. [PubMed](#)
51. Toshiro Hirai *et al.* 2019. *Immunity*. 50(5):1249-1261 . [PubMed](#)
52. Moguche AO *et al.* 2017. *Cell host & microbe*. 21(6):695-706 . [PubMed](#)
53. Wuggenig P, *et al.* 2020. *Commun Biol*. 3:130. [PubMed](#)
54. Ryan NM, *et al.* 2022. *Front Immunol*. 13:932742. [PubMed](#)
55. Gomez S, *et al.* 2022. *J Immunother Cancer*. 10:. [PubMed](#)
56. Dulken BW, *et al.* 2019. *Nature*. 571:205. [PubMed](#)
57. Williams JB, *et al.* 2020. *Nat Commun*. 0.876388889. [PubMed](#)
58. Rosenbaum SR, *et al.* 2020. *Cell Rep*. 30:510. [PubMed](#)
59. Godwin MS, *et al.* 2019. *JCI Insight*. 4:e126070. [PubMed](#)
60. Dahlgren MW *et al.* 2019. *Immunity*. 50(3):707-722 . [PubMed](#)
61. Agashe VV, *et al.* 2018. *J Immunol*. 201:772. [PubMed](#)
62. Zeis P, *et al.* 2020. *Immunity*. 53:775. [PubMed](#)
63. Jaako P, *et al.* 2016. *Leukemia*. 10.1038/leu.2016.159. [PubMed](#)
64. Moufarrij S, *et al.* 2020. *Sci Rep*. 10:3470. [PubMed](#)
65. Muchenditsi A, *et al.* 2017. *Am J Physiol Gastrointest Liver Physiol*. 313:G39. [PubMed](#)
66. Contreras NA, *et al.* 2019. *PLoS Pathog*. 15:e1007890. [PubMed](#)
67. Zaitseva M, *et al.* 2017. *Antiviral Research*. 10.1016/j.antiviral.2017.05.002. [PubMed](#)
68. Tulyeu J, *et al.* 2021. *Curr Protoc*. 1:e283. [PubMed](#)
69. Godwin MS, *et al.* 2021. *Am J Physiol Lung Cell Mol Physiol*. 320:L393. [PubMed](#)
70. Di Pilato M, *et al.* 2021. *Cell*. 184(17):4512-4530.e22. [PubMed](#)
71. Lang JF *et al.* 2019. *Nat Commun*. 10(1):3415 . [PubMed](#)
72. Voeller J, *et al.* 2019. *J Immunother Cancer*. 0.530555556. [PubMed](#)
73. Fedele C, *et al.* 2021. *J Exp Med*. 218: . [PubMed](#)
74. Chao JL, *et al.* 2021. *Cell Rep Med*. 2:100399. [PubMed](#)
75. Mykkänen O, *et al.* 2014. *PLoS One*. 9:114790. [PubMed](#)
76. Platteel ACM, *et al.* 2018. *Front Immunol*. 1.544444444. [PubMed](#)
77. Li K, *et al.* 2020. *Nat Commun*. 0.795138889. [PubMed](#)
78. Säwen P *et al.* 2018. *eLife*. 7 pii: e41258. [PubMed](#)
79. Sharma M, *et al.* 2019. *Immunometabolism*. 1. [PubMed](#)
80. Seenappa LM, *et al.* 2022. *NPJ Vaccines*. 7:128. [PubMed](#)
81. Schulze J, *et al.* 2021. *Stroke*. 52:2939. [PubMed](#)
82. Chavez JS, *et al.* 2022. *Cells*. 11:. [PubMed](#)
83. Kong IY, *et al.* 2020. *Cell Rep*. 33:108290. [PubMed](#)
84. Goldberg EL, *et al.* 2021. *Cell Metabolism*. . [PubMed](#)
85. Hebbandi Nanjundappa R, *et al.* 2017. *Cell*. 171:655. [PubMed](#)

86. Rezende RM, *et al.* 2019. J Immunol. 203:2621. [PubMed](#)  
 87. Parigger T, *et al.* 2021. Int J Mol Sci. 22:.. [PubMed](#)  
 88. Hendin HE, *et al.* 2022. NPJ Vaccines. 7:42. [PubMed](#)  
 89. Ye Y, *et al.* 2020. Genome Med. 0.557638889. [PubMed](#)  
 90. Samuelson DR, *et al.* 2021. Commun Biol. 4:997. [PubMed](#)  
 91. Jiang W, *et al.* 2021. Cell Rep. 37:110112. [PubMed](#)  
 92. Chang MH, *et al.* 2021. Cell Rep. 37:109902. [PubMed](#)  
 93. Gu Z, *et al.* 2021. Nat Genet. 53:672. [PubMed](#)

**RRID** AB\_493696 (BioLegend Cat. No. 100215)  
 AB\_493697 (BioLegend Cat. No. 100216)

## Antigen Details

<b>Structure</b>	Ig superfamily, CD3/TCR, 20 kD
<b>Distribution</b>	Thymocytes (differentiation dependent), mature T cells, NK-T cells
<b>Function</b>	Antigen recognition, TCR signal transduction, T cell activation
<b>Ligand/Receptor</b>	Peptide antigen/MHC-complex
<b>Antigen References</b>	1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Davis MM. 1990. <i>Annu. Rev. Biochem.</i> 59:475. 3. Weiss A, <i>et al.</i> 1994. <i>Cell</i> 76:263.
<b>Gene ID</b>	<a href="#">12502</a>


## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

FITC anti-mouse CD3, PE anti-mouse CD3, Purified anti-mouse CD3, Alexa Fluor® 647 anti-mouse CD3, Alexa Fluor® 488 anti-mouse CD3, Pacific Blue™ anti-mouse CD3, Alexa Fluor® 700 anti-mouse CD3, PerCP/Cyanine5.5 anti-mouse CD3, PE/Cyanine7 anti-mouse CD3, APC/Cyanine7 anti-mouse CD3, Brilliant Violet 421™ anti-mouse CD3, Brilliant Violet 570™ anti-mouse CD3, Brilliant Violet 650™ anti-mouse CD3, Brilliant Violet 785™ anti-mouse CD3, Brilliant Violet 510™ anti-mouse CD3, APC anti-mouse CD3, Ultra-LEAF™ Purified anti-mouse CD3, Brilliant Violet 605™ anti-mouse CD3, Alexa Fluor® 594 anti-mouse CD3, Brilliant Violet 711™ anti-mouse CD3, Biotin anti-mouse CD3, PE/Dazzle™ 594 anti-mouse CD3, APC/Fire™ 750 anti-mouse CD3, Brilliant Violet 750™ anti-mouse CD3, TotalSeq™-A0182 anti-mouse CD3, TotalSeq™-B0182 anti-mouse CD3, Spark Blue™ 550 anti-mouse CD3, Spark NIR™ 685 anti-mouse CD3, TotalSeq™-C0182 anti-mouse CD3, APC/Fire™ 810 anti-mouse CD3, PE/Fire™ 640 anti-mouse CD3, Spark YG™ 570 anti-mouse CD3, PE/Fire™ 700 anti-mouse CD3, PE/Cyanine5 anti-mouse CD3, Spark Blue™ 574 anti-mouse CD3 Antibody, Spark Violet™ 423 anti-mouse CD3, PE/Fire™ 810 anti-mouse CD3, Spark Red™ 718 anti-mouse CD3

## Product Data



C57BL/6 mouse splenocytes stained with 17A2 Alexa Fluor® 700

use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587